Study of treat-to-target in Crohn's and colitis
Part of Digestive system clinical trials.
This study looks at how well a treat-to-target approach works for people with Crohn's disease or ulcerative colitis in everyday medical care. By reviewing your medical history over the past 2 years, researchers hope to learn how to better manage these conditions and prevent long-term damage.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 or older.
- You have had Crohn's disease or ulcerative colitis for at least 2 years.
- Your medical records for the last 2 years must be available for review.
- You have not taken any experimental drugs or been in other clinical trials in the past 2 years.
- You have not had surgery to remove your entire colon and rectum (proctocolectomy).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at blood and/or tissue “molecular” (cell-level) reasons why treatments don’t fully work in adults with Crohn’s disease or ulcerative colitis. If you are starting a biologic or small-molecule medicine and still have moderate to severe symptoms, you may be able to contribute to research that helps improve future care.
This trial tests new therapies for people with moderate to severe Crohn's disease or ulcerative colitis. It may help if your standard treatments aren't working well enough.
This study looks at patients with ulcerative colitis or Crohn's disease who are on Medicare and taking medication for their condition. It will check how often infections happen and aims to understand infection risks better.
This study tests advanced treatments for people with moderate to severe Crohn's disease or ulcerative colitis who haven't responded to at least one previous therapy. It aims to find better options for managing these conditions.
This trial tests whether “treat-to-target” care—guided by regular symptom checks, telemonitoring, and patient education—works better than standard follow-up when starting adalimumab for ulcerative colitis. It aims to help control inflammation more effectively and reduce flare-ups.
This study looks for “biomarkers” (lab markers, like substances in blood or tissue) that may predict how Crohn’s disease or ulcerative colitis will go and how patients may respond. It may help doctors choose better monitoring or treatments in the future.
Hear when a new Crohn’s disease trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.